既往研究表明lncRNA NR2F1-AS1的差异表达与癌症的预后密切相关，但结论仍存在争议。因此，我们进行了荟萃分析和生物信息学分析，探讨LncRNA NR2F1-AS1与癌症预后的相关性。从2023年1月25日开始，我们在PubMed、Embase、Cochrane Library和Web of Science上检索相关研究。我们使用具有 95% 置信区间 (CI) 的汇总风险比 (HR) 和比值比 (OR) 来确定 LncRNA NR2F1-AS1 对人类癌症生存和临床病理特征的重要性。对 11 个国家中 637 名患者的荟萃分析纳入的文章表明，LncRNA NR2F1-AS1 的上调与癌症患者的总生存期较短相关（HR = 1.46，95%Cl 1.06-2.01，p = 0.02）。此外，LncRNA NR2F1-AS1的过表达可预测TNM肿瘤分期（OR = 3.37，95%Cl 2.07-5.48，p < 0.00001）和远处转移（OR = 0.18，95%Cl 0.06-0.48，p = 0.0007） 。然而，年龄(OR = 1.10,95%Cl 0.71-1.71,p = 0.34)、性别(OR = 1.26,95%Cl 0.79-2.00,p = 0.34)、淋巴结转移(OR = 1.44,95)的差异%Cl 0.27-7.80, p = 0.67) 或较大的肿瘤尺寸 (OR = 1.56,95%Cl 0.48-5.08, p = 0.46) 没有统计学意义。 LncRNA NR2F1-AS1 的上调与不良预后和晚期临床病理特征相关的肿瘤患者。

Previous studies have shown that the differential expression of lncRNA NR2F1-AS1 is closely related to the prognosis of cancer, but the conclusion is still controversial. Therefore, we conducted a meta-analysis and bioinformatics analysis to explore the correlation between LncRNA NR2F1-AS1 and cancer prognosis.From the beginning to 25 January 2023, we searched for correlational studies on PubMed, Embase, the Cochrane Library, and Web of Science. We used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the importance of LncRNA NR2F1-AS1 for survival and clinicopathological features of human cancers.The meta-analysis of 637 patients in the 11 included articles showed that upregulation of LncRNA NR2F1-AS1 was associated with shorter overall survival (HR = 1.46,95%Cl 1.06-2.01, p = 0.02) in cancer patients. In addition, overexpression of LncRNA NR2F1-AS1 predicted TNM tumor stage (OR = 3.37, 95%Cl 2.07-5.48, p < 0.00001), and Distant metastasis (OR = 0.18, 95%Cl 0.06-0.48, p = 0.0007). However, the difference in age (OR = 1.10,95%Cl 0.71-1.71, p = 0.34), gender (OR = 1.26,95%Cl 0.79-2.00, p = 0.34), Lymph node metastasis (OR = 1.44,95%Cl 0.27-7.80, p = 0.67) or larger tumor size (OR = 1.56,95%Cl 0.48-5.08, p = 0.46) was not statistically significant.Upregulation of LncRNA NR2F1-AS1 was associated with poor prognosis and advanced clinicopathologic features of tumor patients.